Skip to content

A clinical trial of postoperative analgesia effect of different dosages of ropivacaine on pleural cavity after thoracoscopic surgery

A clinical trial of postoperative analgesia effect of different dosages of ropivacaine on pleural cavity after thoracoscopic surgery

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-16008819
Enrollment
Unknown
Registered
2016-07-11
Start date
2016-08-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

thoracoscopic surgery

Interventions

Group A:Intrapleural injection of 0.75% ropivacaine 20 ml
Group B:Intrapleural injection of 0.75% ropivacaine 15 ml
Group C:Intrapleural injection of 0.75% ropivacaine 10 ml

Sponsors

The First Affiliated Hospital of Wenzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Eligible subjects aged 18 years or older, ASA I to III, and scheduled for thoracoscopic surgery

Exclusion criteria

Exclusion criteria: Exclusion of amide local anesthetic allergies, thoracic surgery history or chest infection,chronic pain, Severe central neurologic diseases,patients with liver and renal insufficiency,history of alcohol and opioid dependence, the recent use of opioid drugs or drugs interaction with ropivacaine, inability to carry out NRS test, patients with BMI=30kg/m2 or =15kg/m2.

Design outcomes

Primary

MeasureTime frame
Pain score when coughing after operation;

Secondary

MeasureTime frame
ain score when deep breathing after operation;Pain score on natural breath after operation;Patient’s satisfaction;extra analgesic consumption;

Countries

China

Contacts

Public ContactXuzhong Xu

The First Affiliated Hospital of Wenzhou Medical University

xuzhong@263.net+86 13706657799

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026